BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

On May 15, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its investigational anti-PD-L1 antibody BGB-A333 and preclinical data on three early-stage drug candidates will be presented at the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, taking place on June 22-24, 2020 (Press release, BeiGene, MAY 15, 2020, View Source [SID1234558175]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentations:

Title: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors
Abstract #: 9496
Poster Board #: CT253
Session Category: CT01 Phase 1 Adult Clinical Trial
Session Title: Phase 1 Trials in Progress
Lead Author: Jayesh Desai, MBBS, FRACP, Peter MacCallum Center Centre, Australia

Title: BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo
Abstract #: 664
Poster Board #: 11
Session Category: Experimental and Molecular Therapeutics
Session Title: PI3K/AKT/mTOR Inhibitors
Lead Author: Xiao Yang, BeiGene

Title: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models
Abstract #: 3077
Poster Board #: 11
Session Category: Experimental and Molecular Therapeutics
Session Title: Topoisomerases, Tubulin, and Other Small Molecule Therapeutic Agents
Lead Author: Nan Hu, BeiGene

Title: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
Abstract #: 6415
Poster Board #: 9
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Therapeutic Approaches
Lead Author: Xi Yuan, BeiGene